BSX:NYE-Boston Scientific Corporation (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 76.76

Change

0.00 (0.00)%

Market Cap

USD 28.38B

Volume

3.54M

Analyst Target

USD 46.29
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Boston Scientific Corp is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-16 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

+0.12 (+0.11%)

USD 196.14B
MDT Medtronic PLC

+0.06 (+0.07%)

USD 115.25B
STE STERIS plc

+0.34 (+0.14%)

USD 23.37B
ZBH Zimmer Biomet Holdings Inc

+1.21 (+1.14%)

USD 21.67B
SNN Smith & Nephew SNATS Inc

+0.29 (+0.95%)

USD 13.37B
GMED Globus Medical

+0.17 (+0.24%)

USD 9.42B
BIO Bio-Rad Laboratories Inc

+16.55 (+5.24%)

USD 9.32B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 8.85B
PEN Penumbra Inc

+4.74 (+2.54%)

USD 7.80B
GKOS Glaukos Corp

+1.19 (+0.94%)

USD 7.15B

ETFs Containing BSX

UMDV:SW iShares US Medical Device.. 10.05 % 0.00 %

N/A

N/A
EDOC:AU BetaShares Digital Health.. 8.95 % 0.00 %

+0.01 (+0.00%)

N/A
GDOC Goldman Sachs ETF Trust 6.20 % 0.00 %

+0.12 (+0.00%)

USD 0.02B
HHL-U:CA Harvest Healthcare Leader.. 5.13 % 0.00 %

+0.04 (+0.00%)

N/A
HHL-B:CA Harvest Healthcare Leader.. 5.13 % 0.00 %

+0.05 (+0.00%)

N/A
MHCD:CA Middlefield Healthcare Di.. 4.32 % 0.00 %

N/A

CAD 0.16B
BMED BlackRock Future Health E.. 3.94 % 0.00 %

+0.19 (+0.00%)

USD 4.21M
AMAL:LSE Saturna Al-Kawthar Global.. 3.19 % 0.00 %

+0.08 (+0.00%)

USD 0.02B
ASWE:XETRA Saturna Al-Kawthar Global.. 3.10 % 0.00 %

+0.05 (+0.00%)

USD 0.01B
BKUS 2.89 % 0.00 %

N/A

N/A
ASRP:XETRA BNP Paribas Easy ECPI Glo.. 2.51 % 0.00 %

+0.09 (+0.00%)

N/A
PLDR Putnam Sustainable Leader.. 2.13 % 0.00 %

+0.20 (+0.00%)

USD 0.57B
AGOX Adaptive Alpha Opportunit.. 1.90 % 0.00 %

+0.30 (+0.00%)

USD 0.31B
XLVE:CA Mulvihill U.S. Health Car.. 1.74 % 0.00 %

N/A

N/A
FWD AB Disruptors ETF 1.56 % 0.00 %

+0.99 (+0.00%)

USD 0.29B
GENDED:SW UBS (Irl) ETF plc - Globa.. 1.30 % 0.00 %

N/A

N/A
GENDEG:SW UBS (Irl) ETF plc - Globa.. 1.30 % 0.00 %

N/A

N/A
GGUE:XETRA UBS Global Gender Equalit.. 1.26 % 0.00 %

+0.12 (+0.00%)

USD 0.23B
GGUE:F UBS (Irl) ETF Public Limi.. 1.26 % 0.00 %

+0.13 (+0.00%)

N/A
GENDER:SW UBS (Irl) ETF plc - Globa.. 1.26 % 0.00 %

+0.05 (+0.00%)

USD 0.32B
GENDES:SW UBS (Irl) ETF plc - Globa.. 1.26 % 0.00 %

+0.04 (+0.00%)

USD 0.14B
GENDET:SW UBS (Irl) ETF plc - Globa.. 1.26 % 0.00 %

+0.02 (+0.00%)

USD 5.52M
VOOM:XETRA Amundi Global Gender Equa.. 0.87 % 0.00 %

+0.12 (+0.00%)

USD 0.06B
ELLE:LSE Amundi Global Gender Equa.. 0.87 % 0.00 %

+0.13 (+0.00%)

USD 0.06B
ELLE:PA Lyxor Global Gender Equal.. 0.87 % 0.00 %

+0.13 (+0.00%)

N/A
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

+0.26 (+0.00%)

N/A
LNGR 0.00 % 0.50 %

N/A

N/A
PSET Principal Quality ETF 0.00 % 0.29 %

+0.96 (+0.00%)

USD 0.06B
GDNA 0.00 % 0.00 %

N/A

N/A
RYH 0.00 % 0.40 %

N/A

N/A
HHL:CA Harvest Healthcare Leader.. 0.00 % 1.15 %

+0.06 (+0.00%)

N/A
OPEN:LSE iShares Thomson Reuters I.. 0.00 % 0.00 %

+0.14 (+0.00%)

N/A
GEND:LSE Amundi Global Gender Equa.. 0.00 % 0.00 %

+0.02 (+0.00%)

N/A
GENE:LSE UBS (Irl) ETF Public Limi.. 0.00 % 0.00 %

+1.80 (+0.00%)

N/A
GENG:LSE UBS (Irl) ETF plc - Globa.. 0.00 % 0.00 %

+8.75 (+0.00%)

USD 0.05B
BSCU Invesco BulletShares 2030.. 0.00 % 0.00 %

-0.02 (0.00%)

USD 0.95B
AGNG Global X Aging Population.. 0.00 % 0.00 %

+0.09 (+0.00%)

USD 0.06B
AMAP:LSE Saturna Al-Kawthar Global.. 0.00 % 0.00 %

+2.60 (+0.00%)

N/A
AGED:SW iShares Ageing Population.. 0.00 % 0.00 %

+0.04 (+0.00%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 32.78% 88% B+ 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.78% 88% B+ 95% A
Trailing 12 Months  
Capital Gain 41.31% 87% B+ 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 41.31% 87% B+ 92% A
Trailing 5 Years  
Capital Gain 87.49% 95% A 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 87.49% 95% A 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 11.61% 61% D- 74% C
Dividend Return 11.61% 61% D- 69% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 18.54% 97% N/A 56% F
Risk Adjusted Return 62.62% 91% A- 83% B
Market Capitalization 28.38B 94% A 98% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 357.70 35% 9%
Price/Book Ratio 5.19 31% 17%
Price / Cash Flow Ratio 45.32 18% 4%
Price/Free Cash Flow Ratio 31.54 9% 6%
Management Effectiveness  
Return on Equity 9.25% 84% 54%
Return on Invested Capital 7.11% 70% 54%
Return on Assets 4.54% 82% 69%
Debt to Equity Ratio 44.43% 52% 64%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.